TIMP1 and thyroid cancer, nonmedullary, 2: D22 cell-derived xenograft tumors, harboring BRAFV600E and NRASQ61R alone or in combination with TP53R248Q mutation expressed comparable levels of TIMP1, CD63, MMP9 and CD44v6 with those found in the matching PTC, FTC and ATC histotypes (Fig. 2G, H, and Supplementary Figs. 4f, g).